Good stuff, didn't check on MSB's own patents (I need to spend some time wading through that, looking forward to Otherperspective's research on this topic!!!), but not surprised they have come up with their own manufacturing processes that anticipate 3D bioreactor technology and means of maximising the effectiveness of the same.
Bottom line is that I am NOT overly worried or exercised about MSB's and Lonza's ability to shift to 3D bioreactor manufacturing being hindered by third parties, and don't put great (or even any) weight on someone's claim that "Pluristem owns 3D bioreactor technology."
Yeah, right.
Analysis of the EAP, page-410
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.060(4.12%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.39 | $1.698M | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3588 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 10711 | 13 |
View Market Depth
| Last trade - 11.00am 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |